Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation
Open accessAbstract
BACKGROUND: Cystic fibrosis (CF) is caused by inherited mutations in the cystic fibrosis transmembrane conductance regulator gene and results in a lung environment that is highly conducive to polymicrobial infection. Over a lifetime, decreasing bacterial diversity and the presence of Pseudomonas aeruginosa in the lung are correlated with worsening lung disease. However, to date, no change in community diversity, overall microbial load or individual microbes has been shown to correlate with the onset of an acute exacerbation in CF patients. We followed 17 adult CF patients throughout the course of clinical exacerbation, treatment and recovery, using deep sequencing and quantitative PCR to characterize spontaneously expectorated sputum samples RESULTS: We identified approximately 170 bacterial genera, 12 of which accounted for over 90% of the total bacterial load across all patient samples. Genera abundant in any single patient sample tended to be detectable in most samples. We found that clinical stages could not be distinguished by absolute Pseudomonas aeruginosa load, absolute total bacterial load or the relative abundance of any individual genus detected, or community diversity. Instead, we found that the microbial structure of each patient's sputum microbiome was distinct and resilient to exacerbation and antibiotic treatment. CONCLUSION: Consistent with previously reported sputum microbiome studies we found that total and relative abundance of genera at the population level were remarkably stable for individual patients regardless of clinical status. Patient-by-patient analysis of diversity and relative abundance of each individual genus revealed a complex microbial landscape and highlighted the difficulty of identifying a universal microbial signature of exacerbation. Overall, at the genus level, we find no evidence of a microbial signature of clinical stage.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Culture-independent studies comparing bacterial communities at baseline and during exacerbations in the airways of patients with COPD, cystic fibrosis, or bronchiectasis consistently report no increase in bacterial burden and no decrease in community diversity during exacerbations.
“With remarkable consistency, all studies report no increase in bacterial burden and no decrease in community diversity during exacerbations.”
From The microbiome and critical illness (2016) · cites this paper as [137]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 31 · Cited by 135
Research works printed but not linked: 1
- NCBI website [ http://www.ncbi.nlm.nih.gov/sra]
- Authors
- Price, K. E., Hampton, T. H., Gifford, A. H., Dolben, E. L., Hogan, D. A., Morrison, H. G., Sogin, M. L., & O’Toole, G. A.
- Affiliations
- Dartmouth College (US)
- Dartmouth–Hitchcock Medical Center (US)
- Marine Biological Laboratory (US)
- Corresponding author
- O’Toole, George A
- ORCID
- Venue
- Microbiome
- Published
- 2013-11-01
- Volume
- 1
- Issue
- 1
- Pages
- 27-27
- ISSN
- 2049-2618 (ISSN-L)
- PMC
- PMC3971630
- OpenAlex
- W2106855493
- Cited by
- 135
- References
- 31
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 13 · 2020: 14 · 2019: 12 · 2018: 9 · 2017: 13 · 2016: 13 · 2015: 24 · 2014: 12
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Microbiome (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cystic Fibrosis Foundation
- Hitchcock Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute (R01HL074175)
- National Institute of General Medical Sciences (GM103413)
- National Institute of Allergy and Infectious Diseases (R01AI083256, T32AI007363)
- National Institute of Diabetes and Digestive and Kidney Diseases (UH3DK083993)
- National Center for Research Resources
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bacterial biofilms and quorum sensing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Infections and bacterial resistance
- Keywords
- cystic fibrosis, sputum microbiome, disease exacerbation, Pseudomonas aeruginosa, bacterial diversity, microbial community stability, antibiotic treatment response
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review